title: Severe infliximab-induced psoriasis treated with adalimumab switching.
abstract: BACKGROUND
  Antitumor necrosis factor (anti-TNF) agents are a well-established treatment for various medical conditions, including psoriasis and psoriatic arthritis. However, anti-TNF agents may themselves induce psoriasis in some patients.
  
  
  METHODS
  The authors report two cases of patients with severe and refractory infliximab-induced psoriasis.
  
  
  RESULTS
  The patients had good clinical responses after switching to another TNF blocker.
  
  
  CONCLUSIONS
  For severe cases, infliximab withdrawal combined with conventional immunosuppressive psoriasis drugs or with adalimumab may be a therapeutic option.
authors.affiliation: Rheumatology Dermatology Divisions, Clínica de Oncologia, Salvador, Bahia, Brazil.
authors.forename: César
authors.initials: C
authors.lastname: Faillace
authors.forename: Gleison Vieira
authors.initials: GV
authors.lastname: Duarte
authors.forename: Rosângela Santos
authors.initials: RS
authors.lastname: Cunha
authors.forename: Jozélio Freire
authors.initials: JF
authors.lastname: de Carvalho
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D000069285:Infliximab; D017116:Low Back Pain / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000139:chemically induced* / Q000473:pathology; D058566:Sacroiliitis / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069285:Infliximab; D000068879:Adalimumab